Genetic profiling when available showed IDH1 mutations in 16.53% of patients, Alpha-Thalassemia/Mental Retardation (ATRX) positivity in 6.61%, Epidermal Growth Factor Receptor Positive (EGFR) positivity in 23.97%, MGMT promoter methylation in 32.23%, and p53 mutations in 19.01%. The gene discussed is EGFR; the disease is alpha thalassemia spectrum.